You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨勵晶太平洋(0575.HK)大漲逾17% 早泄藥尋求取得臨牀試驗審批
格隆匯 11-18 10:09
格隆匯11月18日丨勵晶太平洋(0575.HK)高開高走,現大漲逾17%,報0.191港元,總市值3.5億港元。勵晶太平洋公佈,旗下治療早泄藥Fortacin正於內地尋求批准將Senstend™ 推出市面,該藥預料將於明年第一季前取得國家藥品監督管理局藥品審評中心的臨牀試驗審批。若於提交日期(11月16日)起計3個月內取得臨牀試驗審批,勵晶太平洋將會收取400萬美元的階段性費用。目前美國Fortacin™️第二階段驗證研究進展穩定,料將於年底完成。若美國食品及藥品監督管理局認同研究結果,關鍵第三階段研究將於明年下半年展開。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account